# Article information:

In silico analysis to identify miR-1271-5p/PLCB4 (phospholipase C Beta 4) axis mediated oxaliplatin resistance in metastatic colorectal cancer | Scientific Reports  
<https://www.nature.com/articles/s41598-023-31331-2>

# Article summary:

1. Colorectal cancer (CRC) is a common malignant disease with high mortality rates, and chemotherapy is the main therapeutic method for CRC.

2. Oxaliplatin (OXA) is a commonly used chemotherapeutic agent for mCRC, but its efficacy is limited by drug resistance mechanisms such as activation of DNA repair systems and epigenetic alterations.

3. MicroRNAs (miRNAs) play essential roles in tumorigenesis and contribute to OXA resistance in CRC, providing an opportunity to develop novel therapeutic strategies. In silico analysis identified the miR-1271-5p/PLCB4 axis as a potential mechanism of acquired OXA resistance in mCRC.

# Article rating:

Appears moderately imbalanced: The article provides some useful information, but is missing several important points or pieces of evidence that would be required to present the discussed topics in a balanced and reliable way. You are encouraged to seek a more balanced perspective on the presented issues by exploring the provided research topics and looking at different information sources.

# Article analysis:

该文章提供了有关结直肠癌和氧化铂耐药性的综述。然而，该文章存在一些潜在的偏见和不足之处。

首先，该文章没有提及可能存在的风险和副作用。虽然氧化铂是治疗结直肠癌的常用药物之一，但它也会导致许多不良反应，如恶心、呕吐、腹泻、口腔溃疡、神经病变等。这些副作用可能会影响患者的生活质量，并且需要医生密切监测。

其次，该文章没有平等地呈现双方。虽然该文章提到了微小RNA在氧化铂耐药性中发挥重要作用的事实，但它没有探讨其他因素对耐药性的影响。例如，肿瘤细胞内部环境和免疫系统状态也可能对氧化铂治疗的有效性产生影响。

此外，该文章未提供足够的证据来支持其主张。尽管作者声称已经通过集成生物信息学方法确定了与氧化铂耐药性相关的关键基因和通路，但他们并没有详细说明这些基因和通路是如何被确定的，也没有提供足够的数据来支持他们的结论。

最后，该文章可能存在宣传内容和偏袒。虽然作者声称需要开发更有效的治疗策略来治疗氧化铂耐药性，但他们并没有探讨其他可能的治疗方法或药物。此外，该文章未提及任何潜在利益冲突或资金来源。

综上所述，该文章提供了有关结直肠癌和氧化铂耐药性的一些信息，但它存在一些潜在的偏见和不足之处。为了更全面地了解这个话题，读者应该寻找其他来源，并仔细评估所有可用证据。

# Topics for further research:

* Risks and side effects of oxaliplatin treatment
* Other factors affecting oxaliplatin resistance in colorectal cancer
* Evidence supporting the identified key genes and pathways
* Other potential treatment strategies for oxaliplatin resistance
* Potential conflicts of interest or funding sources
* Additional sources for a comprehensive understanding of the topic

# Report location:

<https://www.fullpicture.app/item/d6d67dda53ecdd527053f1f81125c8e8>